Hanall Biopharma (009420) — Capital Reinvestment Ratio
Hanall Biopharma (009420) has a Capital Reinvestment Ratio of 0.45x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩7.34 Billion) in capital expenditures (₩3.27 Billion). Check 009420 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Hanall Biopharma Capital Reinvestment Ratio (2011–2024)
This chart tracks Hanall Biopharma's Capital Reinvestment Ratio across 10 annual periods. For the full cash flow conversion analysis, see Hanall Biopharma cash conversion from operations.
Annual Capital Reinvestment Ratio for Hanall Biopharma (2011–2024)
Year-by-year Capital Reinvestment Ratio for Hanall Biopharma from 2011 to 2024. See Hanall Biopharma (009420) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.46x | ₩9.36 Billion | ₩23.07 Billion | ▲ +694.3% |
| 2023 | 0.31x | ₩29.64 Billion | ₩9.20 Billion | ▲ +176.3% |
| 2022 | 0.11x | ₩25.20 Billion | ₩2.83 Billion | ▼ -98.0% |
| 2021 | 5.48x | ₩839.87 Million | ₩4.61 Billion | ▲ +98.9% |
| 2020 | 2.76x | ₩929.29 Million | ₩2.56 Billion | ▲ +2561.8% |
| 2019 | 0.10x | ₩20.49 Billion | ₩2.12 Billion | ▲ +152.7% |
| 2017 | 0.04x | ₩42.14 Billion | ₩1.73 Billion | ▼ -96.0% |
| 2016 | 1.02x | ₩3.95 Billion | ₩4.03 Billion | ▲ +2.6% |
| 2012 | 0.99x | ₩2.20 Billion | ₩2.18 Billion | ▲ +1627.8% |
| 2011 | 0.06x | ₩7.41 Billion | ₩426.70 Million | — |